A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

Inclusion Criteria: 1. Voluntarily sign the informed consent form before starting the activities related to the trial; 2. The Numerical Evaluation Scale (NRS) pain score of the index knee joint at screening is ≥ 4; 3. Subjects must be willing to discontinue all medical and non-medical treatments for osteoarthritis pain except rescue medication (acetaminophen) and not use prohibited analgesics throughout the study ; 4. Male and female subjects of childbearing potential must agree to use highly effective contraceptive measures with their partners from the signing of the informed consent form until 1 month after the last dose of investigational product. Exclusion Criteria: 1. History of other diseases that may involve the target joint; 2. History of major trauma or surgery of knee joint and hip joint in the past year; 3. Plan to undergo surgical procedure during the study; 4. Most or complete loss of mobility; 5. There are other diseases that may confuse the assessment of osteoarthritis pain; 6. There is a neuropsychiatric disease, and the investigator's assessment may affect the evaluation of osteoarthritis (OA) or self-score; 7. There are serious or poorly controlled concomitant diseases; 8. Those who have a clear history of peptic ulcer, bleeding, perforation or obstruction within 1 year before screening, and have been clinically diagnosed; 9. Those who require drug treatment or surgical intervention; 10. History of malignant tumors within 5 years before screening; 11. Have a history of drug abuse, drug abuse and/or alcoholism within 2 years before screening.